All In Biotech

Drug Trial Radar · NCT00168350

Memantine in Patients With Chronic Glaucoma

Last checked: Nov 20, 2026Latest source record: Nov 4, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,179

Actual

Start

Mar 2000

Primary completion

Sep 2006

Study completion Sep 2006

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 82 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized double-masked clinical trial of memantine in patients with glaucoma

Conditions

  • Open-Angle Glaucoma

Interventions

  • memantineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression of glaucoma

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.